Literature DB >> 16988561

Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.

Howard G Birnbaum1, Alan G White, Jennifer L Reynolds, Paul E Greenberg, Mingliang Zhang, Sue Vallow, Jeff R Schein, Nathaniel P Katz.   

Abstract

OBJECTIVES: This study estimates the costs to society of prescription opioid analgesic (RxO) abuse in the United States.
METHODS: Costs associated with RxO abuse were grouped into healthcare, criminal justice, and workplace categories. Costs were estimated by either (1) a quantity method that multiplies the number of RxO abusers derived from various national surveys by the estimated per abuser cost, or (2) an apportionment method that starts with overall (ie, prescription and nonprescription) drug abuse costs for a cost component (eg, police protection) and apportions the share of costs based on the prevalence of RxO abuse relative to overall drug abuse. Medical costs in excess of those for otherwise similar nonabusers were based on an analysis of a large administrative claims database for an employed population using multivariate regression methods.
RESULTS: A lower bound estimate of the costs of RxO abuse in the United States was 8.6 billion dollars in 2001 (or 9.5 billion dollars in 2005 dollars). Of this amount, 2.6 billion dollarswere healthcare costs, 1.4 billion dollars were criminal justice costs, and 4.6 billion dollars were workplace costs.
CONCLUSIONS: The costs of RxO abuse represent a substantial economic burden. Rising trends of RxO abuse suggest an escalating economic and public health burden in coming years in the United States, and potentially, elsewhere.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988561     DOI: 10.1097/01.ajp.0000210915.80417.cf

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  41 in total

1.  Prescription Drug Abuse & Diversion: Role of the Pain Clinic.

Authors:  Khary K Rigg; Samantha J March; James A Inciardi
Journal:  J Drug Issues       Date:  2010

2.  Prescription use disorders in older adults.

Authors:  Raj K Kalapatapu; Maria A Sullivan
Journal:  Am J Addict       Date:  2010-09-21

3.  Increasing pregnancy-related use of prescribed opioid analgesics.

Authors:  Richard A Epstein; William V Bobo; Peter R Martin; James A Morrow; Wei Wang; Rameela Chandrasekhar; William O Cooper
Journal:  Ann Epidemiol       Date:  2013-08       Impact factor: 3.797

4.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

Review 5.  Nonmedical use of prescription opioids: motive and ubiquity issues.

Authors:  James P Zacny; Stephanie A Lichtor
Journal:  J Pain       Date:  2008-03-14       Impact factor: 5.820

6.  Non-medical use of prescription opioids and public health in Canada: an urgent call for research and interventions development.

Authors:  Benedikt Fischer; Jürgen Rehm; Brian Goldman; Svetlana Popova
Journal:  Can J Public Health       Date:  2008 May-Jun

Review 7.  Issues in long-term opioid therapy: unmet needs, risks, and solutions.

Authors:  Steven D Passik
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

8.  Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients.

Authors:  Emlyn S Jones; Brent A Moore; Jody L Sindelar; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2008-09-19       Impact factor: 4.492

9.  The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.

Authors:  Curtis S Florence; Chao Zhou; Feijun Luo; Likang Xu
Journal:  Med Care       Date:  2016-10       Impact factor: 2.983

10.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.